Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study.

Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): subgroup analysis of the ELECT study. Clin Adv Hematol Oncol. 2015 Jun;13(6 Suppl 7):10-1 Authors: Phan AT PMID: 26431405 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research